Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
July 29 2019 - 5:17PM
Amarin Corporation plc (NASDAQ:AMRN) today announced that, in
connection with its previously announced underwritten public
offering of American Depositary Shares (“ADSs”), the underwriters
of the offering have exercised in full their option to purchase up
to an aggregate of 3,333,333 additional ADSs. The exercise of this
option increases the size of the offering to an aggregate of
25,555,556 ADSs at a price to the public of $18.00 per ADS. The
gross proceeds of this offering are expected to be approximately
$460.0 million, before deducting the underwriting discounts and
commissions and other estimated offering expenses payable by
Amarin. The purchase of the additional ADSs closed on July 29,
2019.
Amarin intends to use the net proceeds from the offering (1) to
support the ongoing and expanding commercialization of Vascepa®
(icosapent ethyl) assuming the FDA approves Amarin’s supplemental
new drug application seeking an expanded indication for Vascepa in
the United States based on the positive results of Amarin’s
REDUCE-IT™ study, including (i) doubling the size of its existing
sales force, (ii) increasing branded and non-branded advertising,
and (iii) supporting its expanded commercial operations; (2) to
increase commercial supply of Vascepa from third-party drug product
suppliers; and (3) for general corporate purposes. Amarin also may
use a portion of the net proceeds to acquire strategic assets,
although it currently has no agreements or commitments in this
regard.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC,
Jefferies LLC and Cantor Fitzgerald & Co. acted as the joint
book-running managers for the offering. H.C. Wainwright & Co.,
LLC and Roth Capital Partners acted as the co-managers for the
offering.
The securities described above were offered by Amarin pursuant
to a shelf registration statement on Form S-3ASR (No. 333-216385)
previously filed with the Securities and Exchange Commission (the
"SEC") on March 1, 2017 and automatically became effective upon
filing. A preliminary prospectus supplement related to the offering
has been filed with the SEC and is available on the SEC's website
at http://www.sec.gov. A final prospectus supplement and
accompanying prospectus has been filed with the SEC. Copies of the
final prospectus supplement relating to these securities may be
obtained for free by visiting EDGAR on the SEC's web site at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus may also be obtained by contacting J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717; or by telephone at
(866) 803-9204; or by email at prospectus-eq_fi@jpmchase.com,
Goldman Sachs & Co. LLC, 200 West Street, New York, New York
10282, Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone: (877) 547-6340 or email:
Prospectus_Department@jefferies.com or Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York,
NY 10022; or by email at prospectus@cantor.com.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Amarin
Amarin Corporation plc. is a rapidly growing, innovative
pharmaceutical company focused on developing therapeutics to
improve cardiovascular health. Amarin’s product development program
leverages its extensive experience in polyunsaturated fatty acids
and lipid science. Vascepa (icosapent ethyl) is Amarin's first
FDA-approved drug and is available by prescription in the United
States, Lebanon and the United Arab Emirates. Amarin’s commercial
partners are pursuing additional regulatory approvals for Vascepa
in Canada, China and the Middle East. For more information about
Amarin, visit www.amarincorp.com.
Disclosure Notice
This press release contains forward-looking statements, within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements related to Amarin's public offering of
American Depositary Shares and the FDA’s evaluation of Amarin’s
pending supplemental new drug application, are forward-looking
statements that involve risks and uncertainties. Words such as
"intends," "plans," "expects," "may," "will" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are not promises or guarantees.
These forward-looking statements are based upon Amarin's current
expectations. Actual events and results and the timing of events
and results could differ materially from those anticipated in such
forward-looking statements. Among the factors that could cause
actual results to differ materially from those described or
projected herein are the following: risks related to the
underwriters’ consummation of their obligation to purchase the
securities, whether Amarin will be able to satisfy its obligations
to close the offering and the risk that Amarin will not use the
proceeds from the offering in the manner contemplated, as well as
the risks, uncertainties and other matters detailed in Amarin's
filings with the U.S. Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K, its most recent
Quarterly Report on Form 10-Q and the preliminary prospectus
supplement relating to the offering and filed on July 17, 2019.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they were made. Amarin undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise, except as required by law.
Amarin contact information:
Investor Relations:
Elisabeth Schwartz Investor Relations and Corporate
Communications Amarin Corporation plc In U.S.: +1 (908)
719-1315investor.relations@amarincorp.com Lee M. Stern Solebury
Trout In U.S.: +1 (646) 378-2992lstern@soleburytrout.com
Media Inquiries: Gwen Fisher Corporate
Communications Amarin Corporation plc In U.S.: +1 (908)
325-0735 pr@amarincorp.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024